title: Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
abstract: Peptide receptor scintigraphy with [(111)In-DTPA(0)]octreotide (a stabilized radiolabeled somatostatin (SS) analogue, OctreoScan) is widely used for the visualization and staging of somatostatin receptor-positive tumors. The application of likewise somatostatin analogues as vehicle for the deliverance of radionuclides to somatostatin receptor-positive targets are now in use for peptide receptor-targeted radionuclide therapy (PRRT). Currently preclinical and clinical investigation are ongoing trying to find the optimal combination of radionuclide and ligand. The anti-tumoral effects of such combinations, like [90Y-DOTA degrees, Tyr(3)]octreotide and [(177)Lu-DOTA degrees, Tyr(3)]octreotate, on SSR-positive solid tumors have been reported. In this study we present the anti-tumor effects of (177)Lu-DOTA-tate on: a) a single SSR-positive cell model and b) on a SSR-positive tumor in a rat liver micrometastatic model, mimicking disseminated disease. (177)Lu-DOTA-tate showed anti-tumoral effects in both cases and significant survival in the PRRT-treated rats. (177)Lu-DOTA-tate is a very promising new treatment modality for SSR-positive tumors, including disseminated disease.
authors.affiliation: Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. breeman@nuge.azr.nl
authors.forename: Wouter A P
authors.initials: WA
authors.lastname: Breeman
authors.forename: Amir
authors.initials: A
authors.lastname: Mearadji
authors.forename: Astrid
authors.initials: A
authors.lastname: Capello
authors.forename: Bert F
authors.initials: BF
authors.lastname: Bernard
authors.forename: Casper H J
authors.initials: CH
authors.lastname: van Eijck
authors.forename: Eric P
authors.initials: EP
authors.lastname: Krenning
authors.forename: Marion
authors.initials: M
authors.lastname: de Jong
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D008187:Lutetium / Q000627:therapeutic use*; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D017481:Receptors, Somatostatin / Q000378:metabolism; D015996:Survival Rate; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; D017481:Receptors, Somatostatin; C121107:octreotide, DOTA-Tyr(3)-; D008187:Lutetium; D015282:Octreotide